NVZMY (NVZMY) Stock Price & Analysis
NVZMY (NVZMY) rose 5.03% to USD 59.04 as of June 10, 2026 at 02:16 UTC, according to Nexqual real-time market data.
NVZMY last closed at USD 56.21; the session ranged USD 57.78–59.73 on volume of 20,307 shares. Market capitalization is $27.53B, with a 52-week range of USD 49.9–75.99 (PNK). Source: Nexqual, June 10, 2026 at 02:16 UTC.
Key Statistics (as of June 10, 2026 at 02:16 UTC)
| Price | USD 59.04 |
|---|---|
| Change | ▲ 5.03% (up) |
| Previous Close | USD 56.21 |
| Open | USD 58.74 |
| Day Range | USD 57.78 – 59.73 |
| 52-Week Range | USD 49.9 – 75.99 |
| Volume | 20,307 shares |
| Market Cap | $27.53B |
| Exchange | PNK |
Technical Analysis (NVZMY)
Nexqual's technical model rates NVZMY "NEUTRAL" based on 3 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 02:16 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 53.01 (neutral) |
| vs SMA50 | Below (USD 59.48) |
| MACD | -0.6 (negative) |
Analyst Ratings (NVZMY)
Wall Street analysts rate NVZMY "None" based on 3 analysts, with a mean price target of USD 71.33 (range USD 57–83), per Nexqual as of June 10, 2026 at 02:16 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 71.33 |
| High Target | USD 83 |
| Low Target | USD 57 |
| Buy / Hold / Sell | 2 / 0 / 1 |
Earnings (NVZMY)
| Revenue Estimate | $8.26B |
|---|
Source: Nexqual, June 10, 2026 at 02:16 UTC.
Financials & Fundamentals (NVZMY)
| Total Revenue | $4.20B |
|---|---|
| Revenue Growth (YoY) | +3.90% |
| Gross Margin | +55.86% |
| Operating Margin | +24.42% |
| Profit Margin | +14.21% |
| ROE | +5.39% |
| Debt / Equity | 29.42 |
| Current Ratio | 1.67 |
| Total Cash | $327.20M |
| Total Debt | $3.21B |
| Free Cash Flow | $813.16M |
Source: Nexqual, June 10, 2026 at 02:16 UTC.
Financial Health Score (NVZMY)
Nexqual rates NVZMY's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 02:16 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 56%, operating 24% |
| Balance Sheet | Strong — $327M cash vs $3.21B debt |
| Cash Flow | Mixed — FCF $813M, slim 2.6% margin |
| Efficiency | Mixed — ROE 5%, ROA 3.8% |
Ownership (NVZMY)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +5.17% |
| Shares Outstanding | 412.48M |
| Float | 344.43M |
Source: Nexqual, June 10, 2026 at 02:16 UTC.
Leadership (NVZMY)
NVZMY is led by Ester Baiget (age 54), President & CEO, per Nexqual as of June 10, 2026 at 02:16 UTC.
| President & CEO | Ester Baiget (age 54) |
|---|---|
| Executive VP & CFO | Rainer Lehmann (age 50) |
| Chief Operating Officer | Anders Lund (age 52) |
| Chief Scientific Officer | Claus Crone Fuglsang (age 57) |
| Executive Vice President of People & Stakeholder Relations | Morten Enggaard Rasmussen (age 49) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NVZMF | NOVONESIS A S | USD 60 | ▲ 3.84% |
| GVDNY | Givaudan SA | USD 79.01 | ▲ 9.8% |
| CLPBY | Coloplast AS | USD 6.06 | ▲ 1% |
| SGSOY | SGS SA | USD 11.29 | ▲ 1.26% |
| SYIEY | Symrise Ag | USD 23.38 | ▲ 6.37% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:16 UTC. This page is informational and not investment advice.